
Dimerix Gains New Human Evidence Supporting DMX-200 Kidney Disease Target
BiotechnologyDimerix gains human evidence linking CCR2 activity to poorer FSGS outcomes, strengthening the rationale for DMX-200 as its Phase 3 ACTION3 trial progresses.Nik HillJournalist · 2 min readIn this storyASX…
Read report ↗






